obesity. Obesity due to excess calories
Conditions
Interventions
Intervention 1: Only Placebo, 8 tablets a day for 8 weeks (insoluble starch). Intervention 2: moderate aerobic training, 3 times a week (24 sessions, every session 45 minutes) for 8 week plus Placebo.
Placebo
Lifestyle
Treatment - Drugs
Only Placebo, 8 tablets a day for 8 weeks (insoluble starch)
moderate aerobic training, 3 times a week (24 sessions, every session 45 minutes) for 8 week plus Placebo
L-carnitine, 8 tablets daily for 8 weeks (each tablet contains 250 mg of L-carnitine) without aerobic training
L-carnitine, 8 tablets daily for 8 weeks (each tablet contains 250 mg of L-carnitine) plus moderate aerobic training, 3 times a week (24 sessions, every session 45 minutes) for 8 week
Sponsors
Vice-chancellor for research, Tabriz Nutrition Research Center, Tabriz University of Medical Science
Eligibility
Sex/Gender
Female
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: women with BMI = 30, %BF=30, age 20-50 years old. Exclusion criteria: any disease that influence metabolic parameters in this trial (liver, cardiovascular, kidney or gastrointestinal diseases, hypo/hyper thyroidism, orthopedic problems, Romatoid artritis, diabetes, hypertension), pregnancy, receiving any vitamin or mineral supplements, people who have usual aerobic training program (more than 3 times a week, 2 hours every time), any special diet.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| L-carnitine serum value. Timepoint: Baseline and at the end of intervention. Method of measurement: kit & spectrophotometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting serum insulin values & Insulin resistance index. Timepoint: Baseline and at the end of intervention. Method of measurement: chemiluminescance & HOMA formula.;Fasting serum glucose values. Timepoint: Baseline and at the end of intervention. Method of measurement: Enzymatic method, automatic analyzer.;Fasting srum lipid profile (LDL,HDL,total cholesterol,TG). Timepoint: Baseline and at the end of intervention. Method of measurement: Enzymatic method, with special kits for assessing TG, HDL, total cholestrol and Friedewald equation for assessing LDL cholestrol.;Serum inflammatory values (IL-6 ,IL-10, hs-CRP). Timepoint: Baseline and at the end of intervention. Method of measurement: hs-CRP assess with immunotorbidometric method andIL-6& IL-10 with elayza method.;Serum indices of oxidative stress (TAC,MDA). Timepoint: Baseline and at the end of intervention. Method of measurement: TAC with special kits, MDA with chemical-calorimetric & reaction with tiobarbitoric acid.;Antropometric indicators (weight, height, BMI, Waist circumference, hip circumference, Waist to Hip Ratio). Timepoint: Baseline and at the end of intervention. Method of measurement: physical exam.;Measurement of Peak Aerobic Capacity - VO2max. Timepoint: Baseline and at the end of intervention. Method of measurement: With Rockport Walking Test.;Body Fat %. Timepoint: Baseline and at the end of intervention. Method of measurement: ACSM formula and measurement of skin fold thickness according to three site measurements. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMina Karimi
Tabriz University Of Medical Sciences
Outcome results
None listed